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PGIMER, Chandigarh, IndiaA B S T R A C TObjectives: This study aimed to explore and understand the perspec-
tives of a small group of stakeholders involved in health technology
assessment (HTA) for evidence-informed decision making on policy in
the Indian health system. Methods: Semi-structured interviews were
conducted in April-June 2013 with policymakers, academicians, indus-
try experts, and community representatives in India to understand
their knowledge of, position regarding, and interest in HTA. A semi-
structured questionnaire was designed on the basis of a World Health
Organization framework for evidence-informed health care policy-
making. Results: Seven key informant interviews were conducted to
represent the various stakeholders. Although there is a good under-
standing of HTA among the national-level policymakers, academi-
cians, civil society representatives, and industry experts, there is lack
of knowledge about the subject among policymakers at the lower
level. There is a positive perception about producing and using HTAee front matter Copyright & 2014, International S
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ndence to: Bhavesh Jain, Abt Associates, A10, Greefor decision making among all the stakeholders interviewed. Never-
theless, at the national level, institutions prefer to treat the use
of HTA evidence with caution because the capacity for adopting
evidence-based tools in the health system is very limited.
Conclusions: This small-size stakeholder analysis suggests a mixed
response in implementing HTA in India. There are, however, factors
involved in implementing such tools that can be dealt with using
various approaches. Finally, there is a positive view on the national
level toward pushing the HTA agenda forward to improve the
decision-making process in health care.
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Using evidence is one of the most important and rational
approaches to health care policymaking; this is especially impor-
tant in settings in which resources are constrained [1], and health
technology assessment (HTA) is an important tool in these
situations [2]. HTA has been deﬁned as “a form of policy research
that systematically examines short- and long-term consequen-
ces, in terms of health and resource use, of the application of a
health technology, a set of related technologies or technology
related issues” [3]. The goal of HTA is to support informed
policymaking, and economic evaluation forms one of the core
components of HTA studies.
In many developed countries, HTA plays a key role in
improving efﬁciency in the use of health care resources, espe-
cially in the reimbursement for drugs [4]. HTA could potentially
also have an impact on policymaking in developing countries
such as India, which are characterized by a huge demand for
health care, low public sector expenditures, and high private
out-of-pocket expenditures [5]. In Asia, Thailand has successfullyused HTA for the market approval process and for establishing a
protocol for reimbursement [6]. There is increasing emphasis on
the use of evidence-based tools for future investments and for
decision making in the Indian health care system [1]. The High
Level Expert Group report on Universal Health Coverage by the
Planning Commission of India highlights the need for using
economic evidence for policymaking in India [7]. Tested tools
such as KNOW ESSENTIALS facilitate evidence-informed health
care decision making in settings in which resources are limited
and in which there is an absence of formal HTA [8]. This is also
important in light of the poor quality of economic evaluations in
developing countries, where these studies can be misleading in
terms of making well-informed decisions [9]. Collaborative ini-
tiatives such as SIGNET have been undertaken to build the
capacity of Indian health care professionals in HTA [10].
Currently, there is limited understanding about how policy-
makers perceive such evidence-building tools and whether stud-
ies providing evidence based on economic evaluations, such as
cost-effectiveness analysis, would be useful in policymaking or
program evaluation. Therefore, it is essential to understand theociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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Table 1 – Topic list for discussion with stakeholders.
Variables Topic list
Stakeholder’s
knowledge
Understanding of HTA in India
Level of use of HTA for prioritizing health
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evidence-building tools such as HTA are taken into account in
decision making. In this study, analysis of a small group of
stakeholders was undertaken to understand their knowledge,
interest, position, possible (methodological and political) barriers,
and other factors affecting the use of evidence in decision making.and interest for
HTA
care intervention
Instances of use of HTA or economic
evaluations or other evidence-based
decision tools used for policymaking
Stakeholder’s
position
on using HTA in
India
Positive or negative position to support or
reject use of HTA and why?
Prospects of using HTA in the current
context of the public health systems
Stakeholder’s
perception
What kind of inﬂuence/impact does the
research ﬁnding have on policy decision
making
Investments made in enhancing or
encouraging the use of evidence such as
economic evaluation or HTA
Existing and
emerging
factors
inﬂuencing the
use of economic
evaluation
or HTA
Key challenges in utilization and
institutionalization of HTA
Factors enhancing smooth
implementation of HTA at the health
systems level
Stakeholder-
speciﬁc
issues
Decision makers: Users of research
3 Current process of policymaking and
prioritizing in the public health system?
3 Current level of use of HTA in selecting an
appropriate intervention drug or
equipment
3 Critera for selection or prioritizing of public
health intervention/drug/equipment?
3 Sources of information currently used for
generating information to support policy
decision making?
3 How HTA can be institutionalized in the
current government policymaking
process?
Industry/researcher:
3 How industry is involved in generating the
information for decision making
3 Role the industry and researchers/analyst
can play in promoting the use of
HTA
Community organization/nongovernment
organizations (NGOs)Methods
The study adopts steps recommended by Varvasovszky and
Brugha [11] to conduct stakeholder analysis that includes iden-
tifying and approaching stakeholders, collecting and analyzing
data, and presenting and using ﬁndings. Key stakeholders were
identiﬁed using the World Health Organization (WHO) framework
for evidence-informed health care policymaking and also
through expert opinion [12]. The framework helps to analyze
various constraints on using research for setting priorities, gen-
erating and disseminating knowledge, and describing key ele-
ments of evidence-informed policymaking in health care.
Evidence-informed health care policymaking is an approach to
policy decisions that aims to ensure that decision making is well
informed by the best available research evidence [13].
The study includes stakeholders who are promoting and
producing HTA and also policymakers and other potential users
of HTA in India. They include decision makers in government,
industry experts, health insurance experts, academicians, civil
society representatives, and bodies that provide technical assis-
tance to government. Two key experts (an academician in the
area of HTA and a professional worker in the health care
industry) from India were consulted to identify stakeholders
and subsequently contact them.
A semi-structured interview was designed on the basis of the
WHO framework for capacity development for evidence-
informed health care policymaking [12]. An initial topic list
(Table 1) was designed for interviewing stakeholders, covering
topics related to institutional mechanisms, and the capacity and
interest of various stakeholders in producing and using HTA. Two
experts also helped in reviewing the content of the topic list. This
helped to improve the validity of the content and of the study
overall. Participants were contacted primarily through e-mails.
Interviews were conducted at the participants’ workplace in
person.
Interviews for which approval for recording was obtained
were transcribed. Written notes were taken during interviews
for which recording was not permitted by the participant.
Because the topic list was related directly to the research ques-
tions, the content of interviews was clustered accordingly. This
analysis was done using the grounded theory approach [14]. Key
points were grouped according to categories of research ques-
tions. Useful quotes from the interviews were highlighted for
each group of questions and are presented in the ﬁndings.3 Role in pushing the agenda of use of
evidence (economic evaluation or HTA) in
policymaking?
3 Use of HTA by NGOs in selecting health
care intervention for their target
populations?
3 How NGOS have institutionalized the
process of evidence-based policymaking in
their own health care settings?
HTA, health technology assessment.Results
In total, seven key informant interviews were conducted to
represent various stakeholders (Table 2).
Knowledge and Position of Stakeholders on HTA
Interviews suggest the existence of a basic knowledge and
understanding of HTA as a tool for informing decision making.
The interviews, however, touched on only some of the four
components of HTA, namely, medical, social, ethical, and eco-
nomic. The decision maker at the state level had only limited
understanding of HTA (P3) and believed that only medical aspects
are covered by HTA. Regarding the position of stakeholders onHTA, government agencies at the national level are pushing the
concept of HTA by identifying the roles of different organizations,
and developing systems to use HTA.
Table 2 – Description of stakeholders who partici-
pated in the study
Stakeholder Participant Ref.
Decision maker A secretary for Health Research
Department to the Government
of India
P1
Decision maker A director of apex public health
technical assistance body to
National Rural Health Mission,
National Health Systems
Resource Centre (NHSRC),
Government of India
P2
Decision maker An executive director of state-level
organization, responsible for
procuring medical drugs,
equipment, and other
consumable for the public
health systems
P3
Civil society
representative
A senior health care researcher at
the national level and health
care activist working in the area
of community health
P4
Academician A head of health technology unit
at the NHSRC
P5
Health
insurance
expert
A senior health care insurance
expert and advisor to the
Planning Commission of India
P6
Industry expert An industry expert who is also
working with an international
medical device company
P7
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own Indian government mechanism (of HTA), and health
research governance were both responsibilities of my depart-
ment in the government. It comes as one of the mandates.
Then, alongside debate for 12th plan, a debate was going on;
what will the Indian Council of Medical Research (ICMR) do?
What will the health research department do? What will the
health department do? What will other agencies do for health
research? The Planning Commission also felt that such a
board (Medical Technology Board) is necessary. (P1)
Even civil society and academics are positive about advancing
the agenda of evidence-informed decision making, including HTA
in decision making.
As a Senior advisor, I insist that we should advise the Ministry
to start an HTA unit and government should have their own
institutional structure for doing HTA; otherwise we would
keep on getting program guidelines, which are already pro-
grammed with their own technology package and the Govern-
ment of India will only implement these guidelines (rather
than questioning package and technology itself). (P4)Interest and Inﬂuence of Stakeholders on HTA
The analysis reveals that stakeholders have their own organiza-
tional interest in promoting economic evaluations and HTA.
Apex institutions such as the ICMR have their own mandate to
provide good quality assessment for better decision making in
public health programs and overall in the health care sector.
A national-level think tank to the Ministry of National Health
System Resource Centre (NHSRC) also has a keen interest in HTA.
Accordingly, there are efforts at the national level to promote
evidenced-based decision making.We have been seized with the HTA issue for the last 2 years.
We also want to have a proper HTA mechanism; we want to
have a proper institutional system so that ultimately what-
ever advice we give to government, government hospitals,
their doctors or the people who are going to purchase equip-
ment—they do something based on evidence. (P1)
The NHSRC is inﬂuencing the HTA domain in India by creating
a pool of skilled professionals in HTA and using them in
conducting HTA.
We realized that there was not much representation of South-
east Asian candidates in international platforms and pro-
grammes of HTA, so we devised a national level program in
India with almost same faculty as a WHO-sponsored fellow-
ship. We have already trained about 150 people in HTA. The
best part is that, having completed this fellowship, these
candidate are clubbed into teams and each team prepares
an HTA report for our organization. (P5)
Perspective of Stakeholders on HTA
Stakeholders from academics and technical assistance bodies
feel that decisions have always been based on certain criteria,
either published evidence or expert opinion. They feel that HTA
can formalize the informal decision-making process and might
help in creating a system for better decision making. Academics
and civil society representatives also expressed similar views.
There is a way of how you look at HTA. By acronymizing the
term, you are giving it a speciﬁc boundary, a package, a certain
existence as a tool or as a discipline or as a domain that it does
not enjoy at present. However, there has always been technology
assessment. Decisions have always been made about inclusion
(of drugs/technology) in programs; regulators, professionals and
patients have always made decisions about health issues. HTA
brings a certain discipline into each of these processes. (P2)
When asked about the effect of HTA on policymaking, partic-
ipants expressed the view that HTA is becoming more important in
lower- and middle-income countries, due to budget constraints
and the need for input in decision making. Even industry and
insurance providers are interested in HTA because it promotes
competition and provides information on the best possible options.
Government is worried as they have a limited budget, and
even this year the annual budget is only 2% more than last
year’s allocation, though it was supposed to be 25%. In a
system where funding health care is not yet based on
reimbursement, the utility of HTA and the potential of HTA
is far more important. (P5)
Policymakers will welcome this initiative because at this
moment they have no choices. They remain under stress
due to a limited budget. (P1)
When concerns were raised about sustained investment and
establishing a governance model for rolling out HTA programs in
a major way, stakeholders felt that not much investment would
be required because only trained manpower would be needed;
the National Institute of Clinical Excellence (NICE), UK, model
could be exploited.
We don’t need much investment for HTA programs. The
question is how to create a very well-coordinated small
structure with good automation. At most, you will have to
get consultants. (P1)
The benchmark of how HTA will be done in my understanding
is NICE UK, which recognizes and is grounded in the philos-
ophy of sciences. (P4)
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Policymaking and HTA
A key factor affecting the use of evidence is the availability
of a health care data repository for the public and private
health system; this is a key requirement for the HTA program.
Another factor that affects the use of evidence is policymakers’
awareness and knowledge of tools such as HTA and economic
evaluation.
Building capacities is ﬁrst requirement of better understand-
ing of philosophy of sciences. (P2)
The HTA challenge is only one aspect of the need to scale up
in terms of human resources. For everything we do here in
India, we ﬁnd a problem with human resources. In compar-
ison with the size of the country and the gigantic problem, the
pool of [HTA trained] people is smaller. (P1)
The HTA unit of the NHSRC has included a health systems
integration module in its reports, which will make it easier for
policymakers to understand and adopt solutions.
In reports on HTA that we publish, we include a health
systems integration model and do not leave it in a void. We
ensure that these reports reach the desks of the appropriate
authorities in charge and tell them that this component could
also be a component of your services—for example, a national
program for the control of blindness can actually have a
mobile eye surgical unit, and how this should function. (P5)
Another important factor that might affect the use of HTA
studies is a lack of awareness on the part of public and civil
society organizations. Although there have been some interac-
tions between various organizations on the national level, there
is a need for wider consultation including regional organizations,
state bodies, and so forth. This would enhance acceptance from
all parts of society. This would bring about a change in the
mindset and ultimately change the approach toward policymak-
ing from opinion based to evidence based.
These are areas where you have to scale up the pool ﬁrst and
change mindset of people. (P1)
Because we don’t have patient and users’ committees, that
kind of consumer awareness is absent. If Industry is involved,
it becomes a whitewashing mechanism and bureaucracy is
created which might have nexus with industry. You also have
some civil society group or something which doesn’t know the
issues, is not equipped to handle them. (P2)Discussion
In this study, a small group of stakeholders was interviewed to
understand their knowledge of, position regarding, and interest
in HTA. Our analysis revealed that most of India’s stakeholders
believe that HTA should be promoted as a tool for evidence-
informed policymaking. The key issue, however, is capacity
building for producing and using HTA in decision making. There
is a fair amount of knowledge at the national level; however,
personnel at the state level have limited understanding of the
subject. Stakeholders believe that the use of HTA remains a
challenge, even if HTA and economic evaluation studies are
produced. Because of a poor understanding of HTA, policy-
makers, especially at the lower level, are not able to apply the
results toward decision making. The HTA unit of the NHSRC has
also incorporated a section of health systems integration into its
HTA studies, making it more user-friendly.Although industry is interested in HTA, there is no investment
or inclination toward HTA due to limited regulatory mechanisms.
Currently, the Drug Controller General of India requires only
clinical data, and not economic data, to approve a drug for the
market. Accordingly, there is no adequate platform for discussing
key issues related to the quantity and quality of economic
evaluations and HTA studies. In addition, the limited availability
and mostly poor quality of studies hamper the use of evidence by
policymakers.
Despite limited use and understanding of HTA, India has
already taken steps toward it by starting sensitization and basic
workshops on HTA. The NHSRC, Amrita Institute of Medical
Sciences and Research Centre, and IIT Chennai have jointly
organized 1-week workshops and by 2013 trained around 150
professionals in HTA. The Medical Technology Assessment Board
has been established by the Government of India under the aegis
of the ICMR. Furthermore, a dedicated unit in the NHSRC is
working on HTA. Despite the ongoing dialogue between agencies
such as the ICMR and the NHSRC, the need remains for the wider
involvement of other stakeholders to ensure success and sus-
tainability. In Thailand, a national-level program called the
Health Intervention and Technology Assessment Program has
been established and its sustainability is ensured through the
involvement of other stakeholders from public and multilateral
agencies [15]. Experience from other Asian countries shows that
measures such as developing national guidelines for producing
economic evaluation studies, creating a database, making the
process of using evidence transparent, and educating policy-
makers and the public can address some barriers to using
evidence [16].
Thailand, which has been successful in progressing rapidly
toward achieving universal health care, is still struggling in using
economic evaluations in setting priorities. The main reasons for
this are difﬁculties in changing the current process for decision
making, political acceptability, and organizational structures [17].
Although India is also looking forward to achieving universal
health coverage with affordable health care solutions, the
country will need to face some of these challenges. Although
policymakers are looking at NICE and its integration in distribut-
ing health care in the United Kingdom, several contextual differ-
ences between the two health systems have to be taken into
consideration.
There are some caveats that need be considered in regard to
our ﬁndings. First, this analysis covers only a very small number
of stakeholders. Thus, the opinions of only a fraction of stake-
holders might be represented. Further studies are required with a
much larger number of stakeholder consultations. The study also
captures the present perceptions, knowledge, and interest of
stakeholders, and these are subject to change.
In conclusion, this small-size stakeholder analysis suggests
that there is potential for HTA programs to be implemented in
India. A concerted effort, however, from all stakeholders would
be required to build capacities, make investments, and bridge
research policy gaps in evidence building. The experience of HTA
in countries such as Thailand should be leveraged.
To conclude with a quote from one of the stakeholders:
There will never be perfect solutions. There will be only the
best way forward in an imperfect world. (P2)Acknowledgments
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